Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel plus gemcitabine shows antitumour efficacy in patients with advanced NSCLC

By  

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

By Richards Donald   Kuefler Paul   Becerra Carlos   Wilfong Lalan   Gersh Robert   Boehm Kristi   Zhan Feng   Asmar Lina   Myrand Scott   Hozak Rebecca   Zhao Luping   Gill John   Mullaney Brian   Obasaju Coleman   Nicol Steven  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 144-153

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine plus capecitabine has modest activity in the treatment of metastatic renal cancer refractory to or unsuitable for immunotherapy

By  

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

PEFG superior to gemcitabine for advanced pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1499, 2005-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite